Baseline characteristics of patients newly diagnosed with FL diagnosed from 1 September 2004 to 31 August 2012 and followed-up for deaths until 31 December 2018
| . | Source Cohort, n (%) . | Sequenced, n (%) . | |
|---|---|---|---|
| Yes (study cohort) . | No . | ||
| Total | 852 (100.0) | 548 (100.0) | 304 (100.0) |
| Male | 374 (43.9) | 250 (45.6) | 124 (40.8) |
| Female | 478 (56.1) | 298 (54.4) | 180 (59.2) |
| Age at diagnosis, y | |||
| Median (interquartile range) | 64.8 (55.6-73.2) | 63.6 (54.3-72.3) | 66.9 (57.8-74.5) |
| <60 y | 295 (34.6) | 202 (36.9) | 93 (30.6) |
| ≥60 y | 557 (65.4) | 346 (63.1) | 211 (69.4) |
| Transformation to DLBCL | 149 (17.5) | 96 (17.5) | 53 (17.4) |
| Deaths (before 01/01/2019) | 352 (41.3) | 204 (37.2) | 148 (48.7) |
| 5-y survival, % | 74.5 | 78.5 | 68.8 |
| Medical records available | 830 (100.0) | 538 (100.0) | 292 (100.0) |
| First-line management | |||
| Chemotherapy | 355 (42.8) | 223 (41.4) | 132 (45.2) |
| Radiotherapy only | 124 (14.9) | 94 (17.5) | 30 (10.3) |
| Watch and Wait (W&W) | 333 (40.1) | 212 (39.4) | 121 (41.4) |
| Induction rituximab | 6 (0.7) | 5 (0.9) | 1 (0.3) |
| Supportive/palliative care only | 12 (1.4) | 4 (0.7) | 8 (2.7) |
| FLIPI | |||
| Low | 230 (27.7) | 162 (30.1) | 68 (23.3) |
| Intermediate | 191 (23.0) | 120 (22.3) | 71 (24.3) |
| High | 284 (34.2) | 174 (32.3) | 110 (37.7) |
| Not known | 125 (15.1) | 82 (15.2) | 43 (14.7) |
| Stage | |||
| IA | 106 (12.8) | 71 (13.2) | 35 (12.0) |
| IB | 11 (1.3) | 5 (0.9) | 6 (2.1) |
| II | 105 (12.7) | 66 (12.3) | 39 (13.4) |
| III | 140 (16.9) | 101 (18.8) | 39 (13.4) |
| IV | 370 (44.6) | 231 (42.9) | 139 (47.6) |
| Not fully staged | 98 (11.8) | 64 (11.9) | 34 (11.6) |
| B-symptoms | |||
| No | 599 (72.2) | 406 (75.5) | 193 (66.1) |
| Yes | 210 (25.3) | 122 (22.7) | 88 (30.1) |
| Not known | 21 (2.5) | 10 (1.9) | 11 (3.8) |
| Performance status (ECOG) | |||
| 0-1 | 748 (90.1) | 493 (91.6) | 255 (87.3) |
| 2-4 | 75 (9.0) | 41 (7.6) | 34 (11.6) |
| Not known | 7 (0.8) | 4 (0.7) | 3 (1.0) |
| . | Source Cohort, n (%) . | Sequenced, n (%) . | |
|---|---|---|---|
| Yes (study cohort) . | No . | ||
| Total | 852 (100.0) | 548 (100.0) | 304 (100.0) |
| Male | 374 (43.9) | 250 (45.6) | 124 (40.8) |
| Female | 478 (56.1) | 298 (54.4) | 180 (59.2) |
| Age at diagnosis, y | |||
| Median (interquartile range) | 64.8 (55.6-73.2) | 63.6 (54.3-72.3) | 66.9 (57.8-74.5) |
| <60 y | 295 (34.6) | 202 (36.9) | 93 (30.6) |
| ≥60 y | 557 (65.4) | 346 (63.1) | 211 (69.4) |
| Transformation to DLBCL | 149 (17.5) | 96 (17.5) | 53 (17.4) |
| Deaths (before 01/01/2019) | 352 (41.3) | 204 (37.2) | 148 (48.7) |
| 5-y survival, % | 74.5 | 78.5 | 68.8 |
| Medical records available | 830 (100.0) | 538 (100.0) | 292 (100.0) |
| First-line management | |||
| Chemotherapy | 355 (42.8) | 223 (41.4) | 132 (45.2) |
| Radiotherapy only | 124 (14.9) | 94 (17.5) | 30 (10.3) |
| Watch and Wait (W&W) | 333 (40.1) | 212 (39.4) | 121 (41.4) |
| Induction rituximab | 6 (0.7) | 5 (0.9) | 1 (0.3) |
| Supportive/palliative care only | 12 (1.4) | 4 (0.7) | 8 (2.7) |
| FLIPI | |||
| Low | 230 (27.7) | 162 (30.1) | 68 (23.3) |
| Intermediate | 191 (23.0) | 120 (22.3) | 71 (24.3) |
| High | 284 (34.2) | 174 (32.3) | 110 (37.7) |
| Not known | 125 (15.1) | 82 (15.2) | 43 (14.7) |
| Stage | |||
| IA | 106 (12.8) | 71 (13.2) | 35 (12.0) |
| IB | 11 (1.3) | 5 (0.9) | 6 (2.1) |
| II | 105 (12.7) | 66 (12.3) | 39 (13.4) |
| III | 140 (16.9) | 101 (18.8) | 39 (13.4) |
| IV | 370 (44.6) | 231 (42.9) | 139 (47.6) |
| Not fully staged | 98 (11.8) | 64 (11.9) | 34 (11.6) |
| B-symptoms | |||
| No | 599 (72.2) | 406 (75.5) | 193 (66.1) |
| Yes | 210 (25.3) | 122 (22.7) | 88 (30.1) |
| Not known | 21 (2.5) | 10 (1.9) | 11 (3.8) |
| Performance status (ECOG) | |||
| 0-1 | 748 (90.1) | 493 (91.6) | 255 (87.3) |
| 2-4 | 75 (9.0) | 41 (7.6) | 34 (11.6) |
| Not known | 7 (0.8) | 4 (0.7) | 3 (1.0) |
ECOG, European Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index.
Rituximab, cyclophosphamide, vincristine, prednisolone (R-CVP; n = 215); R-CHOP (n = 81); chlorambucil only (n = 42); FCR (n = 10); other (n = 7).